EP1620405A2 - Pyrazolamide und sulfonamide als natriumkanal modulatoren - Google Patents

Pyrazolamide und sulfonamide als natriumkanal modulatoren

Info

Publication number
EP1620405A2
EP1620405A2 EP04751090A EP04751090A EP1620405A2 EP 1620405 A2 EP1620405 A2 EP 1620405A2 EP 04751090 A EP04751090 A EP 04751090A EP 04751090 A EP04751090 A EP 04751090A EP 1620405 A2 EP1620405 A2 EP 1620405A2
Authority
EP
European Patent Office
Prior art keywords
aryl
pyrazole
carboxamide
chlorophenyl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04751090A
Other languages
English (en)
French (fr)
Inventor
Robert N. Atkinson
Irene Drizen
Robert J. Gregg
Michael F. Gross
Michael E. Kort
Lei Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/427,847 external-priority patent/US20040220170A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP1620405A2 publication Critical patent/EP1620405A2/de
Withdrawn legal-status Critical Current

Links

Definitions

  • the present invention relates to certain pyrazole-amide and pyrazole-sulfonamide compounds that modulate PN3 and are useful for treating neuropathic pain.
  • Sodium channel blockers are effective in the treatment of various disease states including neuropathic pain.
  • Neuropathic pain can be described as pain associated with damage or permanent alteration of the peripheral or central nervous system.
  • Clinical manifestations of neuropathic pain include a sensation of burning or electric shock, feelings of bodily distortion, allodynia, and hyperalgesia.
  • Sodium channel-blocking agents selectively suppress abnormal ectopic neural firing in injured peripheral and central neurons. Alterations in either the level of expression or distribution of sodium channels within an injured nerve, therefore, have a major influence on the pathophysiology of pain associated with this type of trauma.
  • Navl.8 (also known as PN3) is a member of a family of voltage-gated sodium channels. PN3-nulled mutant mice exhibit a pronounced analgesia to mechanical noxious stimuli. Selective "knock down" of PN3 protein in the rat dorsal root ganglion with specific antisense oligodeoxynucleotides prevents hyperalgesia and allodynia caused by either chronic nerve or tissue injury. In both human and animal models of neuropathic pain, there is an increased expression of PN3 at the site of peripheral nerve injury.
  • neuropathic pain patients with neuropathic pain do not respond to non-steroidal anti-inflamatory drugs and resistance or insensitivity to opiates is common.
  • Gabapentin is the market leading treatment for neuropathic pain; its mechanism of action for pain is unknown. As few as 30% of patients respond to gabapentin treatment.
  • the present invention provides such compounds, methods of using them, and compositions that include the compounds.
  • SUMMARY OF THE INVENTION The present invention discloses pyrazole-amides and pyrazole-sulfonamides, a method for modulating PN3 in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds. More particularly, the present invention is directed to compounds of formula (I)
  • Ri is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroarylalkyl;
  • R 2 and R 3 are independently hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, aryl, arylalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR A R B , or (NR A R ⁇ )carbonyl;
  • R A and R B are independently hydrogen, alkyl, or alkylcarbonyl
  • X is O or S
  • R 5 is hydrogen, alkyl, alkylcarbonyl, alkylcarbonyloxy, or heterocyclealkyl; Li is a bond or alkylene; L 2 is a bond or alkylene; A is aryl, cycloalkyl, heteroaryl, or heterocycle; B is aryl, cycloalkyl, heteroaryl, or heterocycle; D is heterocycle wherein the heterocycle is azetidinyl, azepanyl, aziridinyl, azocanyl, 1,1-dioxidothiomorpholinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl, wherein the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyl
  • the present invention discloses compounds of formula (II) that modulate PN3 in mammals and are useful for controlling pain in mammals,
  • R 12 and R 13 are independently hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, aryl, arylalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR A R B , or (NR A R B )carbonyl;
  • R A and R ⁇ are independently hydrogen, alkyl, or alkylcarbonyl; R ⁇ is
  • X is O or S
  • R15 is hydrogen, alkyl, alkylcarbonyl, alkylcarbonyloxy, or heterocyclealkyl
  • R 16 and R 17 are independently hydrogen, alkenyl, alkoxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycle, or heterocyclealkyl;
  • R 18 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, -NRARB, or (NR A R B )alkyl;
  • Li is a bond or alkylene
  • L 2 is absent, a bond, or alkylene
  • A is aryl, cycloalkyl, heteroaryl, or heterocycle
  • B is absent, aryl, cycloalkyl, heteroaryl, or heterocycle
  • D is heterocycle wherein the heterocycle is azetidinyl, azepanyl, aziridinyl, azocanyl, 1,1-dioxidothiomorpholinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl, wherein the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, -NR A R B , or (NR R B )carbonyl.
  • the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alk
  • the present invention discloses compounds that modulate PN3 in mammals and are useful for controlling pain in mammals. These compounds include:
  • Ri is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroarylalkyl;
  • R and R 3 are independently hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, aryl, arylalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR A R B , or (N ARB)carbonyl;
  • R A and RB are independently hydrogen, alkyl, or alkylcarbonyl
  • X is O or S
  • R 5 is hydrogen or alkyl
  • Li is a bond or alkylene
  • L 2 is a bond or alkylene
  • A is aryl, cycloalkyl, heteroaryl, or heterocycle
  • B is aryl, cycloalkyl, heteroaryl, or heterocycle
  • D is heterocycle wherein the heterocycle is azetidinyl, azepanyl, aziridinyl, azocanyl, 1,1-dioxidothiomorpholinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl, wherein the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, -NRAR B , or (NRAR B )carbonyl.
  • the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alkoxy
  • Ri is aryl wherein the aryl is phenyl substituted with 1 halogen substituent wherein a preferred halogen substituent is -Cl;
  • R 2 is hydrogen;
  • R 3 is haloalkyl wherein a preferred haloalkyl is trifluoromethyl;
  • R 4 is
  • Ri is aryl wherein the aryl is phenyl substituted with 1 halogen substituent wherein a preferred halogen substituent is -Cl;
  • R 2 is hydrogen;
  • R 3 is haloalkyl wherein a preferred haloalkyl is trifluoromethyl;
  • R 4 is
  • X is O; D is piperazinyl; Li is a bond; and B is cycloalkyl wherein the cycloalkyl is cyclohexyl.
  • R 2 , R 3 , R 5 , X, A, B, L 1; and L are as defined in formula (I).
  • compounds of formula (I) are disclosed wherein Ri is aryl; R is
  • X is O; Li is a bond; A is piperidinyl; L is alkylene; B is aryl; and R 5 is as defined in formula (I).
  • Ri is aryl wherein the aryl is phenyl substituted with 1 halogen substituent wherein a preferred substituent is -Cl;
  • R 2 is hydrogen;
  • R 3 is alkyl;
  • R 4 is
  • R 5 is as defined in formula (I).
  • Ri is aryl wherein the aryl is phenyl substituted with 1 halogen substituent wherein a preferred substituent is -Cl;
  • R 2 is hydrogen;
  • R 3 is alkyl;
  • R 4 is
  • X is O; Li is a bond; A is piperidinyl; L 2 is alkylene wherein -CH 2 - is preferred; B is aryl wherein the aryl is phenyl; and R 5 is hydrogen.
  • R 12 and R 13 are independently hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, aryl, arylalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR A RB, or (NR A R ⁇ )carbonyl;
  • R A and R B are independently hydrogen, alkyl, or alkylcarbonyl
  • X is O or S
  • R 15 is hydrogen or alkyl
  • Ri 6 and R 17 are independently hydrogen, alkenyl, alkoxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycle, or heterocyclealkyl;
  • R ⁇ 8 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, -NR A R B , or (NR A R B )alkyl;
  • Li is a bond or alkylene
  • L 2 is absent, a bond, or alkylene
  • A is aryl, cycloalkyl, heteroaryl, or heterocycle
  • B is absent, aryl, cycloalkyl, heteroaryl, or heterocycle
  • D is heterocycle wherein the heterocycle is azetidinyl, azepanyl, aziridinyl, azocanyl, 1,1-dioxidothiomorpholinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl, wherein the heterocycle is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, -NR A R B , or (NR A R B )carbonyl.
  • compounds of formula (II) are disclosed wherein Li is a bond; A is heterocycle; L 2 is al
  • aryl is phenyl substituted with 1 alkylsulfonyl substituent.
  • compounds of formula (II) wherein Li is a bond; A is heterocycle wherein the heterocycle is tetrahydropyran; L 2 and B are absent; R 14 is
  • R 12 , R 13 , R 16 and R 1 are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein Li is a bond; A is heterocycle wherein the heterocycle is tetrahydropyran; L 2 and B are absent; R 14 is
  • R 12 and R 16 are hydrogen; R 13 is alkyl or haloalkyl; and R ⁇ 7 is aryl.
  • compositions comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. !l
  • compositions comprising a therapeutically effective amount of a compound of formula (LI) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
  • Another embodiment of the present invention relates to a method for modulating PN3 in a host mammal comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
  • Another embodiment of the present invention relates to a method for modulating PN3 in a host mammal comprising administering a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
  • Another embodiment of the present invention relates to a method for treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
  • Another embodiment of the present invention relates to a method for treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
  • alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
  • Representative examples of alkenyl include, but are not limited to, ethenyl (vinyl), 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkoxy means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • alkoxyalkyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2- ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
  • alkoxycarbonyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
  • alkoxy sulfonyl as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl.
  • alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylcarbonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl- 1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcarbonyloxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
  • alkylene means a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms.
  • Representative examples of alkylene include, but are not limited to, -CH 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and -CH 2 CH(CH 3 )CH 2 -.
  • alkylsulfonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
  • alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • aryl as used herein, means a phenyl group, or a bicyclic or a tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
  • Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkyl group, as defined herein, or another phenyl group.
  • Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkyl group, as defined herein, or another phenyl group.
  • aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl and tetrahydronaphthyl.
  • the aryl groups of this invention can be substituted with 1 , 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxy sulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, -NR A R B , (NR A R ⁇ )carbonyl, or (NR A R B )sulfonyl.
  • arylalkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.
  • carbonyl as used herein, means a -C(O)- group.
  • cyano as used herein, means a -CN group.
  • cycloalkyl as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 8 carbons.
  • examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the cycoalkyl groups of the present invention are optionally substituted with 1, 2, 3, or 4 substituents selected from
  • cycloalkylalkyl as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, and 4-cycloheptylbutyl .
  • halo or halogen as used herein, means -Cl, -Br, -I or -F.
  • haloalkoxy means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2- fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy.
  • haloalkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoro ⁇ entyl.
  • heteroaryl refers to an aromatic five- or six-membered ring wherein 1, 2, 3, or 4 heteroatoms are independently selected from N, O, or S.
  • the five membered rings have two double bonds and the six membered rings have three double bonds.
  • the heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom.
  • heteroaryl also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group, a monocyclic cycloalkyl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group; and tricyclic systems where a bicyclic system is fused to a phenyl group, a monocyclic cycloalkyl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group.
  • heteroaryl include, but are not limited to, benzothienyl, benzoxadiazolyl, cinnolinyl, dibenzofuranyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, and triazinyl.
  • heteroaryl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxy sulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, -NR A R B , (NR A R B )carbonyl, or (NR A R B )sulfonyl.
  • heteroarylalkyl as used herein, means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heteroarylalkyl include, but are not limited to, pyridin-3-ylmethyl and 2-pyrimidin-2-ylpropyl.
  • heterocycle refers to a three, four, five, six, seven or eight membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
  • the three membered ring has zero double bonds.
  • the four and five membered ring has zero or one double bonds.
  • the six membered ring has zero, one, or two double bonds.
  • the seven and eight membered rings have zero, one, two, or three double bonds.
  • the heterocycle groups of the present invention can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom.
  • heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, azocanyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, and thiomorpholinyl.
  • heterocycles of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, oxo, -NR A R B , (NR A R B )carbonyl, or (NR A R ⁇ )sulfonyl.
  • heterocyclealkyl as used herein, means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclealkyl include, but are not limited to, pyridin-3- ylmethyl and 2-pyrimidin-2-ylpropyl.
  • hydroxy as used herein, means an -OH group.
  • hydroxyalkyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.
  • mercapto as used herein, means a -SH group.
  • nitro as used herein, means a -NO 2 group.
  • -NRAR B means two groups, Ri and R , which are appended to the parent molecular moiety through a nitrogen atom.
  • Ri and R 2 are each independently hydrogen, alkyl, or alkylcarbonyl.
  • Representative examples of -NR A R ⁇ include, but are not limited to, amino, methylamino, acetylamino, and acetylmethylamino.
  • (NR A R B )carbonyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NT A R B )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NR A R B )sulfonyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of (NR A R ⁇ )sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • sulfonyl as used herein, means a -SO 2 - group.
  • Stereoisomers can exist as stereoisomers, wherein asymmetric or chiral centers are present.
  • Stereoisomers are designated (R) or (S), depending on the configuration of substituents around the chiral carbon atom.
  • the terms (R) and (S) used herein are configurations as defined in TUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., (1976), 45: 13-30.
  • the present invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention.
  • Stereoisomers include enantiomers, diastereomers, and mixtures of enantiomers or diastereomers.
  • Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution, a technique well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or (3) formation of a diastereomeric salt followed by selective recrystallization of one of the diastereomeric salts.
  • resolution exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) direct separation of the mixture of optical en
  • Pyrazoles of general formula (8) wherein Ri, R 5 , L l5 A, L 2 , and B are as defined in formula (I) and R 2 is alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkoxy, or haloalkyl, can be prepared as described in Scheme 1.
  • Ethyl vinyl ether can be treated with an anhydride of general formula (1), aqueous methylamine, and N,N- dimethylaminopyridine to provide enaminones of general formula (2) as described in Mellor, et. al., Tetrahedron, 56:7255-7267 (2000).
  • Enaminones of general formula (2) can be treated with an anhydride of general formula (1) and pyridine to provide compounds of general formula (3).
  • Compounds of general formula (3) can be treated with hydrazines of general formula (4) to provide pyrazoles which can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (5).
  • Acids of general formula (5) can be treated with oxalyl chloride to provide acid chlorides of general formula (6).
  • Acid chlorides of general formula (6) can be treated with amines of general formula (7) and triethylamine or diisopropylethylamine to provide pyrazoles of general formula (8).
  • Acids of general formula (5) can also be treated with an amine of general formula (7), a carbodiimide including, but not limited to, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or dicyclohexycarbodiimide (DCC), and triethylamine to provide pyrazoles of general formula (8).
  • a carbodiimide including, but not limited to, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or dicyclohexycarbodiimide (DCC), and triethylamine to provide pyrazoles of general formula (8).
  • Pyrazoles of general formula (8) wherein R ⁇ , R 5 , L 1; A, L 2 , and B are as defined in formula (I) and R 2 is alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkoxy, or haloalkyl, can be prepared as described in Scheme 2.
  • Keto esters of general formula (10) can be treated with N-(dimethoxymethyl)-N,N-dimethylamine and an acid including, but not limited to, para-toluenesulfonic acid to provide compounds of general formula (11).
  • esters of general formula (12) can be treated with hydrazines of general formula (4) to provide esters of general formula (12) as described in Menozzi, et. al., J. Het. Chem., 24:1669 (1987).
  • Esters of general formula (12) can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (5).
  • Acids of general formula (5) can be processed as described in Scheme 1 to provide pyrazoles of general formula (8).
  • Esters of general formula (15) can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (16).
  • Acids of general formula (16) can be treated with oxalyl chloride to provide acid chlorides of general formula (17).
  • Acid chlorides of general formula (17) can be treated with amines of general formula (7) and triethylamine or diisopropylethylamine to provide pyrazoles of general formula (18).
  • Pyrazoles of general formula (23), wherein Ri, R 5 , Li, A, L 2 , and B are as defined in formula (I), can be prepared as described in Scheme 4.
  • Esters of general formula (20), prepared using the procedure described in Beck, et. al., J. Het. Chem., 267:267-270 (1987), can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (21).
  • Acids of general formula (21) can be treated with oxalyl chloride to provide acid chlorides of general formula (22).
  • Acid chlorides of general formula (22) can be treated with amines of general formula (7) and triethylamine or diisopropylethylamine to provide pyrazoles of general formula (23).
  • Pyrazoles of general formula (29), wherein R 1 ; R 5 , L 1 ; A, L , and B are as defined in formula (I), can be prepared as described in Scheme 5.
  • Esters of general formula (25) can be treated with potassium cyanide or sodium cyanide to provide esters of general formula (26).
  • Esters of general formula (26) can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (27).
  • Acids of general formula (27) can be treated with oxalyl chloride to provide acid chlorides of general formula (28).
  • Acid chlorides of general formula (28) can be treated with amines of general formula (7) and triethylamine or diisopropylethylamine to provide pyrazoles of general formula (29).
  • Pyrazoles of general formula (8) wherein Ri, R 5 , Li, A, L 2 , and B are as defined in formula (I) and R 2 is alkenyl, alkyl, alkylcarbonyl, alkynyl, or aryl, can be prepared as described in Scheme 6.
  • Esters of general formula (20) can be treated with a palladium catalyst including, but not limited to, dichlorobis[tri(o-tolyl)phosphine]palladium(II) and a tin compound of general formula (30) wherein R 2 is alkenyl, alkyl, alkynyl, aryl, or a vinyl ether including, but not limited to, ethoxyvinyl to provide esters of general formula (31).
  • Esters of general formula (31) can be treated with aqueous base including, but not limited to, potassium hydroxide or sodium hydroxide to provide acids of general formula (32).
  • Acids of general formula (32) can be treated with oxalyl chloride to provide acid chlorides of general formula (33).
  • Acid chlorides of general formula (33) can be treated with amines of general formula (7) and triethylamine or diisopropylethylamine to provide pyrazoles of general formula (8) wherein R is alkenyl, alkyl, alkylcarbonyl, alkynyl, or aryl.
  • Example 1A 4-Dimethylamino- 1,1,1 -trifruoro-but-3-en-2-one Trifluoroacetic anhydride (2.0 g, 9.5 mmol.) was dissolved in dichloromethane (20 mL) and the mixture was cooled to 0 °C with an ice bath. Ethyl vinyl ether (0.69 g, 9.5 mmol) and a catalytic amount of DMAP were added and the mixture was stirred for 30 min. The ice bath was removed and the mixture was warmed to ambient temperature and stirred for an additional 2 h. The mixture was cooled to -5 °C with an ice/brine bath and 40% (w/v) aqueous dimethylamine (3.5 mL) was added.
  • Example IB 3-Dimethylaminomethylene- 1,1,1 ,5 ,5 ,5-hexafluoro-pentane-2,4-dione
  • the product from Example 1A 1.0 g, 6.0 mmol
  • dichloromethane 7 mL
  • Pyridine 0.61 g, 7.7 mmol
  • trifluoroacetic anhydride 1.6 g, 7.7 mmol
  • the mixture was warmed to ambient temperature, diluted with water (75 mL) and extracted twice with dichloromethane (75 mL).
  • the combined extracts were concentrated under reduced pressure to provide 1.3 g of the desired product.
  • Example 1C l-(4-Chloro ⁇ henylV5-trifluoromethyl-lH-pyrazole-4-carboxyIic acid 4-Chlorophenylhydrazine hydrochloride, the product from Example IB, and triethylamine were dissolved in acetonitrile (12 mL) and stirred at ambient temperature for 16 h. The solvent was removed under reduced pressure and the crude material was dissolved in EtOAc/hexanes (1:1) and filtered through a 1/2" silica gel frit. The solvent was removed under reduced pressure and the crude material was dissolved in 1,4-dioxane (15 mL). Aqueous KOH was added and the mixture was heated at reflux for 30 min.
  • Example ID l-(3-chlorophenyl)-4- ⁇ ri-(4-chlorophenyl)-5-(trifluoromethyl)-lH-pyrazol-4- yllcarbonyllpiperazine hydrochloride A solution of the product from Example 1C in dichloromethane (15 mL) was treated with oxalyl chloride and a catalytic amount of DMF. The mixture was allowed to stir at ambient temperature for 1 h and the solvent and excess oxalyl chloride were removed under reduced pressure. The material was re-dissolved in dichloromethane (15 mL) and treated with l-(3-chlorophenyl)piperazine and triethylamine and allowed to stir at ambient temperature for 1 h.
  • Example 2 l- ⁇ ri-(4-chlorophenyl)-5-(trifluoromethyl)-lH-pyrazol-4-yncarbonyll-4- cyclohexylpiperazine A solution of the product from Example 1C and N-cyclohexylpiperazine were processed as described in Example ID to provide the desired product. MS (DCI/NH 3 ) m/z 441 (M-HC1) + .
  • Example 3A l-(3-Chlorophenyl)-5-trifluoromethyl-lH ⁇ pyrazole-4-carboxylic acid 3-Chlorophenylhydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example 1C to provide the desired product.
  • Example 3B l-(3-chlorophenyl)-N-r3-(methylsulfonyl)phenvn-5-(trifluoromethyl)-lH-pyrazole-4- carboxamide
  • a solution of the product from Example 3 A and 3-(methanesulfonyl)aniline were processed as described in Example ID to provide the desired product.
  • Example 4A l-(3-Methylphenyl)-5-trifluoromethyl-lH-pyrazole-4-carboxylic acid 3-Methylphenylhydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • Example 4B l-(3-methylphenyl)-N-r3-(methylsulfonyl)phenyll-5-(trifluoromethyl)-lH-pyrazole-4- carboxamide
  • Example 5A l-(4-Methylphenyl)-5-trifluoromethyl-lH-pyrazole-4-carboxylic acid 4-Methylphenylhydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • MS (ESI-) m/z 269 (M-H) " MS (ESI-) m/z 269 (M-H) " .
  • Example 5B l-(4-methylphenyl)-N-[3-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-lH-pyrazole-4- carboxamide
  • Example 6A l-(2-Methoxyphenyl)-5-trifluoiOmethyl-lH-pyrazole-4-carbo ⁇ ylic acid 2-Methoxyphenylhydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • MS (ESI-) m/z 285 (M-H) ⁇
  • Example 6B l-(2-methoxyphenyl)-5-(trifluoromethyl -N-r3-(trifluoromethyl)benzyll-lH-pyrazole-4- carboxamide
  • MS (ESI+) m/z 444 (M+H) + were processed as described in Example ID to provide the desired product.
  • Example 7 N-r2-(4-chlorophenyl)ethyll-l-(2-methoxyphenyl)-5-(trifluoromethyl)-lH-pyrazole-4- carboxamide A solution of the product from Example 6A and 2-(4-chlorophenyl)ethylamine were processed as described in Example ID to provide the desired product.
  • Example 8A l-Cyclohexyl-5-trifluoromethyl-lH-pyrazole-4-carboxylic acid Cyclohexylhydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • Example 8B l-cvclohexyl-5-(trifluoromethyl)-N-r3-(tri ⁇ luoiOmethyl)benzyl1-lH-pyrazole-4-carboxamide
  • a solution of the product from Example 8A and 3-trifluoromethylbenzyl amine were processed as described in Example ID to provide the desired product.
  • Example 8 A A solution of the product from Example 8 A and 3-(methanesulfonyl)aniline were processed as described in Example ID to provide the desired product.
  • MS (DCI/NH 3 ) m/z 433 (M+NH 4 ) + ; 1H NMR (DMSO-d 6 ) ⁇ 10.80 (s, IH), 8.33 (s, IH), 8.08 (s, IH), 7.94 (dt, IH, J 7.1, 2.0 Hz), 7.69-7.62 (m, 2H), 4.37-4.24 (m, IH), 3.21 (s, 3H), 1.99-1.80 (m, 6H), 1.75- 1.63 (m, IH), 1.53-1.34 (m, 2H), 1.32-1.17 (m, IH).
  • Example 10A l-(7-Chloro-quinolin-4-yl)-5-trifluoromethyl-lH-pyrazole-4-carboxylic acid (7-Chloroquinolin-4-yl)-hydrazine hydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • Example 10B N-r2-(4-chlorophenyl ' )ethvn-l-(7-chloroquinolin-4-yl) ⁇ 5-(trifluoromethyl)-lH-pyrazole-4- carboxamide
  • a solution of the product from Example 10 A and 2-(4-chlorophenyl)ethylamine were processed as described in Example ID to provide the desired product.
  • Example 11A l-(l-Benzylpiperidin-4-yl)-5-trifluoromethyl-lH-pyrazole-4-carboxylic acid (l-Benzylpiperidin-4-yl)-hydrazine dihydrochloride, the product from Example IB, and triethylamine were processed as described in Example IC to provide the desired product.
  • Example 11B l-(l-benzylpiperidin-4-yl)-N-r3-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-lH-pyrazole-4- carboxamide
  • a solution of the product from Example 11A and 3-(methylsulfonyl)aniline were processed as described in Example ID to provide the desired product.
  • Example 12A Ethyl 2-acetyl-3-(dimethylamino acrylate A mixture of ethyl acetoacetate(3.9 g, 30 mmol), p-toluenesulfonic acid monohydrate (catalytic amount) and N,N-dimethylformamide dimethyl acetal (5.3 g, 45 mmol) was stirred at 100 °C for 1.5 h. The mixture was distilled under vacuum (10 Torr). The distillate collected between 145 °C and 165 °C afforded 3.1 g of the desired compound as a yellowish oil.
  • Example 12B l-(4-Chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylic acid ethyl ester
  • An acetonitrile solution of the product from Example 12A (0.87 g, 4.7 mmol) and triethylamine (650 ⁇ L, 4.70 mmol) was added to a suspension of 4-chlorophenylhydrazine hydrochloride (0.84 g, 4.7 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at 25° C for 10 h.
  • Example 12C l-(4-Chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylic acid
  • the product from Example 12B (1.2 g, 4.5 mmol) was dissolved in methanol (10 mL) and treated with a solvent mixture of THF (12 mL), 20% KOH (12 mL) and methanol (12 mL). The solution was stirred at 25 °C for 10 h. The reaction mixture was then diluted with ethyl acetate (100 mL) and was partitioned between ethyl acetate (150 mL) and water (300 mL).
  • Example 12D 1 -(4-Chlorophenyl)-5-methyl- lH-pyrazole-4-carbonyl chloride
  • dichloromethane 30 mL
  • oxalyl chloride 230 ⁇ L, 2.60 mmol
  • the reaction mixture was stirred at 25 °C for 3 h and the solvent was evaporated to afford 610 mg of the title compound as a white solid.
  • Example 13 N-(l-benzylpiperidin-4-yl)-l-(4-chlorophenyl)-5-methyl-lH-pyrazole-4-carboxamide A solution of the product from Example 12D and l-benzylpiperidin-4-ylamine were processed as described in Example ID to provide the desired product.
  • Example 14A l-(4-Chlorophenyl)-5-methyl-lH-pyrazole-3-carboxylic acid ethyl ester
  • 4-chlorophenylhydrazine hydrochloride 1.0 g, 5.6 mmol
  • triethylamine 780 ⁇ L, 5.60 mmol
  • ethyl acetopyruvate 820 ⁇ L, 5.60 mmol
  • the reaction mixture was diluted with dichloromethane (200 mL) and washed with water (250 mL).
  • Example 14B l-(4-Chlorophenyl)-5-methyl-lH-pyrazole-3-carboxylic acid A solution of the product from Example 14A were processed as described in Example 12C to provide the desired product. MS (ESI) m/z 237 (M+H) + .
  • Example 14C l-(4-Chlorophenyl)-5-methyl-lH-pyrazole-3-carbonyl chloride A solution of the product from Example 14B were processed as described in Example 12D to provide the desired product.
  • Example 14D l-(4-chlorophenyl)-N-r2-(4-chlorophenyl ethyll-5-methyl-lH-pyrazole-3-carboxamide
  • MS (ESI) m/z 390 (M+H) + ; 1H NMR (DMSO-d 6 ) ⁇ 10.23 (s, IH), 8.40-8.36 (m, 2H), 8.13-8.06 (m, IH), 7.68- 7.58 (m, 6H), 3.22 (s, 3H), 2.58 (s, 3H).
  • Example 15 l-(4-chlorophenyl)-5-methyl-N-r3-(trifluoromethyl)benzyll-lH-pyrazole-3-carboxamide A solution of the product from Example 14D and 3-(trifluoromethyl)benzylamine were processed as described in Example ID to provide the desired product.
  • Example 16 l-(4-chlorophenyl)-5-methyl-N-r3-(methylsulfonyl)phenyn-lH-pyrazole-3-carboxamide A solution of the product from Example 14D and 3-(methanesulfonyl)aniline were processed as described in Example ID to provide the desired product.
  • Example 17 A l-(4-Chlorophenyl)-5-hydroxy-lH-pyrazole-4-carboxyhc acid l-(4-Chloro-phenyl)-5-iodo-lH-pyrazole-4-carboxylic acid ethyl ester (0.5 g, 1.3 mmol) (J. Heterocycl. Chem. 1987, 267, 267-270) in EtOH (40 mL) was treated with 20% KOH (10 mL) for 1 h at room temperature. The reaction mixture was concentrated and the residue was partitioned in EtOAc/H 2 O.
  • Example 17B 1 -(4-Chlorophenyl)-5-hydroxy-lH-pyrazole-4-carbonyl chloride
  • Example 17A (0.06 g, 0.3 mmol) in CH 2 C1 2 (5 mL) was treated with oxalyl chloride (0.1 mL), catalyzed by the addition of a few drops of DMF. After the reaction mixture was stirred at room temperature for 1 h the solvent was evaporated to give the acid chloride.
  • Example 17C N-benzyl-l-(4-chlorophenyl)-5-hydroxy-lH-pyrazole-4-carboxamide
  • Example 17B was dissolved in THF (3 mL) and reacted with benzylamine (0.50 g, 0.45 mmol) in the presence of triethylamine (0.1 mL) and a catalytic amount of DMAP. The reaction mixture was stirred at ambient temperature for 16 h, the solvents were evaporated in vacuo and the remaining residue was purified by silica gel chromatography (elution with 50% EtOAc/hexandes) to yield the title compound.
  • Example 18 l-(4-chlorophenyl -5-hvdroxy-N-r3-(methylsulfonyl)phenyll-lH-pyrazole-4-carboxamide
  • a solution of Example 17B was treated with 3-(methylsulfonyl)aniline hydrochloride in the presence of triethylamine and a catalytic amount of DMAP as described in Example 17C to yield the title compound.
  • Example 19 A l-(4-Chlorophenyl)-5-cyano-lH- ⁇ yrazole-4-carboxylic acid ethyl ester Ethyl 5-chloro-l-(4-chlorophenyl)-lH-pyrazole-4-carboxylate (I. Heterocycl. Chem. 1987, 267, 267-270) (0.24 g, 0.80 mmol) in acetonitrile (30 mL) was stirred at reflux for 16 h with potassium cyanide (0.12 g, 1.8 mmol) and 18-crown-6 (0.5 g).
  • Example 19B l-(4-Chlorophenyl)-5-cyano-lH-pyrazole-4-carboxylic acid
  • Example 19 A (0.2 g, 0.7 mmol) was stirred at ambient temperature in EtOH (10 mL) and 20 % KOH (5 mL) for 1 h. Ethanol was evaporated in vacuo and the remaining residue was dissolved in water and acidified to yield 0.12 g of the title compound as a tan solid.
  • MS (DCL/NH 3 ) m/z 265 (M+NH 4 ) + ; 1H NMR (CDC1 3 ) 7.56 (d, 2H), 7.70 (d, 2H), 8.23 (s, IH), 12.80 (br s, IH).
  • Example 19C l-(4-chloiOphenyl)-5-cyano-N-r3-(methylsulfonyl) ⁇ henyl1-lH-pyrazole-4-carboxamide
  • Example 19B (0.1 g, 0.4 lrrmol) in CH C1 2 was treated with oxalyl chloride (0.1 mL), catalyzed by the addition of DMF.
  • the reaction mixture was stirred at ambient temperature for 2 h, the solvents were removed in vacuo and the obtained acid chloride was dissolved in THF (3 mL) and reacted with 3-methylsulphonylaniline hydrochloride (0.1 g, 0.5 mmol) in the presence of triethylamine (0.14 mL, 1.0 mmol) and a catalytic amount of DMAP.
  • the reaction mixture was stirred at ambient temperature for 16 h, evaporated and purified by chromatography to yield the title compound as a tan solid.
  • Example 20A l-(4-Chlorophenyl)-5-vinyl-lH-pyrazole-4-carboxylic acid ethyl ester l-(4-Chloro-phenyl)-5-iodo-lH-pyrazole-4-carboxylic acid ethyl ester (0.76 g, 2 mmol) ( J. Heterocycl. Chem. 1987, 267, 267-270) was heated for 5 h at reflux in toluene (10 mL) with tributylvinyltin (0.95 g, 3.0 mmol) and dichlorobis[tri(o-tolyl) phosphine]paIladium(II) (16 mg).
  • Example 20B l-(4-Chlorophenyl)-5-vinyl-lH-pyrazole-4-carboxylic acid
  • Example 20A (0.6 g, 2.2 mmol) in EtOH (5 mL) was treated with 20 % KOH (2 mL) for 2 h at ambient temperature. Ethanol was evaporated and the aqueous layer was acidified to yield 0.4 g of the title compound as a tan solid.
  • Example 20C l-(4-Chlorophenyl)-5-vinyl-lH-pyrazole-4-carbonyl chloride
  • the product from Example 20B (0.4 g, 1. 6 mmol) in CH 2 C1 2 (5 mL) was treated with oxalyl chloride (0.5 mL) in the presence of a catalytic amount of DMF.
  • the reaction mixture was stirred at ambient temperature for 2 h upon which the solvent was evaporated to yield the title compound.
  • Example 20D l-(4-chlorophenyl -N-r3-(methylsulfonyl phenvn-5-vinyl-lH-pyrazole-4-carboxamide
  • Example 20C (0.054 g, 0.20 mmol) in THF (3 mL) was stirred for 16 h at ambient temperature with 3-methylsulphonylaniline hydrochloride (0.052 g, 0.25 mmol) in the presence of triethylamine (0.7 mL, 0.5 mmol) and a catalytic amount of DMAP. The reaction mixture was evaporated in vacuo and the residue was chromatographed to yield the title compound as a solid.
  • Example 21 l-(4-chlorophenyl)-N-(3,4-dichlorobenzyl)-5-vinyl-lH-pyrazole-4-carboxamide
  • the product from the Example 20C (0.054 g, 0.20 mmol) in THF (3 mL) was stirred for 16 h at ambient temperature with 3,4-dichlorobenzylamine (0.044 g, 0.25 mmol) in the presence of triethylamine (0.35 mL, 0.25 mmol) and a catalytic amount of DMAP.
  • the reaction mixture was evaporated in vacuo and the residue was chromatographed to yield the title compound as a solid.
  • Example 22B 5-Acetyl-l-(4-chlorophenyl)-lH-pyrazole ⁇ 4-carboxylic acid
  • Example 22A (0.2 g, 0.7 mmol) in EtOH (5 mL) was treated with 20 % KOH (2 mL) for 2 h at ambient temperature. Ethanol was evaporated and the aqueous layer was acidified to yield 0.14 g of the title compound as a tan solid.
  • Example 22C 5-Acetyl- 1 -(4-chlorophenyl)- lH-pyrazole-4-carbonyl chloride
  • Example 22B (0.2 g, 0.8 mmol) in CH 2 C1 2 (5 mL) was treated with oxalyl chloride (0.4 mL) in the presence of a catalytic amount of DMF. The reaction mixture was stirred at ambient temperature for 2 h upon which the solvent was evaporated to yield the tiltle compound.
  • Example 22D 5-acetyl-l-(4-chlorophenyl)-N-r3-(methylsulfonyl)phenyl]-lH-pyrazole-4-carboxamide
  • Example 22C (0.048 g, 0.17 mmol) in THF (3 mL) was stirred for 16 h at ambient temperature with 3-(methylsulfonyl)aniline hydrochloride (0.043 g, 0.21 mmol) in the presence of triethylamine (0.7 mL, 0.5 mmol) and a catalytic amount of DMAP. The reaction mixture was evaporated in vacuo and the residue was chromatographed to yield the title compound as a solid.
  • Example 23 5-acetyl-l-(4-chlorophenyl)-N-(3,4-dichlorobenzyl)-lH-pyrazole-4-carboxamide
  • Example 22C (0.048 g, 0.17 mmol) in THF (3 mL) was stirred for 16 h at ambient temperature with 3,4-dichlorobenzylamine (0.035 g, 0.20 mmol) in the presence of triethylamine (0.35 mL, 0.25 mmol) and a catalytic amount of DMAP. The reaction mixture was evaporated in vacuo and the residue was chromatographed to yield the title compound as a solid.
  • Example 24 l-(4-chlorophenyl ' )-N-(2-methoxybenzyl)-5-methyl-lH-pyrazole-3-carboxamide A solution of the product from Example 14D and 2-methoxybenzylamine were processed as described in Example ID to provide the desired product.
  • Example 25 l-(4-chlorophenyl)-5-methyl-N-(2-methylbenzyl)-lH-pyrazole-3-carboxamide A solution of the product from Example 14D and 2-methylbenzylamine were processed as described in Example ID to provide the desired product.
  • TTIdotoxin Resistant Currents in Neuropathic Pain Model
  • Sodium channels are critical elements in the transduction of action potentials in excitable tissues such as nerve and muscle, and as such, participate in many physiological processes.
  • selective blockers could, in principle, be effective analgesics without undesirable effects observed with nonselective sodium channel blockers.
  • excitability of sensory neurons can be modulated by various receptors and ion channel processes, sodium channels directly regulate neuronal excitability.
  • DRG dorsal root ganglion
  • TTX-R sodium currents were studied in dorsal root ganglion (DRG) neurons from rats 14 days following spinal nerve ligation (SNL).
  • DRG dorsal root ganglion
  • Small size neurons (C-fiber neurons ⁇ 25 ⁇ m) from L4 and L5 DRG were dissociated from rats, and Na + currents were measured in the presence of 100 nM TTX by whole-cell current recording.
  • the total Na + current density was reduced by 42% in L5 DRG neurons from SNL rats compared to L5 DRG neurons from sham operated rats. This reduction in current density was attributable to a significant reduction in TTX-resistant, but not TTX-sensitive currents.
  • this decrease in TTX-R current was observed only in the L5 injured region, whereas there was a significant increase in TTX-R currents in the L4 uninjured region.
  • TTX-R currents were significantly decreased in L5 ganglia, the increased TTX-R currents in L4 ganglia may be responsible for the firing and sensation of neuropathic pain.
  • a Navl.8 channel inhibitor may attenuate neuropathic pain by blocking currents in L4 DRG neurons, as well as by blocking currents generated at the nociceptive peripheral terminals.
  • Representative compounds of the present invention demonstrated IC 5 o s from about 500 nM to about 3 ⁇ M.
  • Compounds of the present invention inhibit the PN3 sodium channel and are therefore useful as analgesics for neuropathic pain.
  • the present invention also provides pharmaceutical compositions that comprise compounds of the present invention.
  • the pharmaceutical compositions comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers.
  • the pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally , intracistemally, intravaginally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray.
  • parenterally refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as, but not limited to, lactose, glucose and sucrose; starches such as, but not limited to, corn starch and potato starch; cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as, but not limited to, cocoa butter and suppository waxes; oils such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols; such as propylene glycol; esters such as, but not limited to, ethyl oleate and
  • compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate) and suitable mixtures thereof.
  • Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • the absorption of the drug in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound may be mixed with at least one inert, pharmaceutically acceptable carrier or excipient, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, poly vinylpyrroli done, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents
  • compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such carriers as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned carriers.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as
  • the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating carriers or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like.
  • the preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.
  • Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which may be required.
  • Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) which is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration.
  • the selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated.
  • a therapeutically effective amount of one of the compounds of the present invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form.
  • therapeutically effective amount means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • salts means salts derived from inorganic or organic acids.
  • the salts can be prepared in situ during the final isolation and purification of compounds of the present invention or separately by reacting the free base of a compound of a compound of the present invention with an inorganic or organic acid.
  • Representative acid addition salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, dihydrochloride, hydrobromide, hydroiodide, 2- hydroxyethansulfonate (isethionate), lactate, maleate, fumarate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, (L) tartrate, (D) tartrate, (DL) tartrate, thiocyan
  • Representative examples include, but are not limited to N-(l-benzylpiperidin-4-yl)-5-methyl-l-phenyl-lH- pyrazole-4-carboxamide hydrochloride, N-( 1 ⁇ benzylpiperidin-4-yl)-5-methyl- 1 -phenyl- 1H- pyrazole-4-carboxamide (L) tartrate, or N-(l-benzylpiperidin-4-yl)-5-methyl-l-phenyl-lH- pyrazole-4-carboxamide benzene sulfonate.
  • esters of compounds of the present invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • examples of pharmaceutically acceptable, non-toxic esters of the present invention include Ci-to-C 6 alkyl esters and C 5 -to-C cycloalkyl esters, although Ci-to-C 4 alkyl esters are preferred.
  • Esters of the compounds of the present invention may be prepared according to conventional methods.
  • Representative examples include, but are not limited to, ethyl 4-(4- ⁇ [(l-benzylpiperidin-4- yl)amino]carbonyl ⁇ -5-methyl-lH-pyrazol-l-yl)benzoate or methyl 4-(4- ⁇ [(l-benzylpiperidin- 4-yl)amino]carbonyl ⁇ -5-methyl-lH-pyrazol-l-yl)benzoate.
  • pharmaceutically acceptable amide means to non-toxic amides of the present invention derived from ammonia, primary Ci-to-C 6 alkyl amines and secondary C ⁇ -to-C 6 dialkyl amines. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, Ci-to-C 3 alkyl primary amides and Ci-to-C dialkyl secondary amides are preferred. Amides of the compounds of the present invention may be prepared according to conventional methods.
  • Representative examples include, but are not limited to, l-[4-(aminocarbonyl)phenyl]-N-(l-benzylpiperidin-4-yl)-5-methyl-lH-pyrazole-4- carboxamide or ⁇ -(l -benzylpiperidin-4-yl)- 1 - ⁇ 4-[(dimethylamino)carbonyl]phenyl ⁇ -5- methyl- l ⁇ -pyrazole-4-carboxamide.
  • prodrug or "prodrug,”as used herein, represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like. Prodrugs of the present invention may be rapidly transformed in vivo to compounds of the present invention, for example, by hydrolysis in blood.
  • Representative examples include, but are not limited to, N-acetyl-N-(l-benzylpiperidin-4-yl)-5-methyl-l-phenyl-lH-pyrazole-4- carboxamide, N-(l-benzylpiperidin-4-yl)-N-(2,2-dimethylpropanoyl)-5-methyl-l-phenyl-lH- pyrazole-4-carboxamide, or ethyl l-benzylpiperidin-4-yl[(5-methyl-l-phenyl-lH-pyrazol-4- yl)carbonyl]carbamate.
  • the present invention contemplates compounds of the present invention formed by synthetic means or formed by in vivo biotransformation.
  • the compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates.
  • solvated forms including hydrated forms, such as hemi-hydrates.
  • pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the invention.
  • the total daily dose of the compounds of this invention administered to a human or lower animal may range from about 0.01 to about 125 mg/kg/day.
  • more preferable doses can be in the range of from about 0.1 to about 150 mg/kg/day.
  • the effective daily dose can be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04751090A 2003-05-01 2004-04-29 Pyrazolamide und sulfonamide als natriumkanal modulatoren Withdrawn EP1620405A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/427,847 US20040220170A1 (en) 2003-05-01 2003-05-01 Pyrazole-amides and sulfonamides as sodium channel modulators
PCT/US2004/013530 WO2004099154A2 (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators

Publications (1)

Publication Number Publication Date
EP1620405A2 true EP1620405A2 (de) 2006-02-01

Family

ID=35529848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04751090A Withdrawn EP1620405A2 (de) 2003-05-01 2004-04-29 Pyrazolamide und sulfonamide als natriumkanal modulatoren

Country Status (4)

Country Link
EP (1) EP1620405A2 (de)
JP (1) JP2006525355A (de)
CA (1) CA2525325A1 (de)
MX (1) MXPA05011775A (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6195684B2 (ja) * 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
JP2019504840A (ja) * 2016-01-28 2019-02-21 ソルヴェイ（ソシエテ アノニム） ハロゲン置換ジケトン、ピラゾール化合物およびピラゾール化合物の製造方法
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246847A (zh) * 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
KR20010013977A (ko) * 1997-06-19 2001-02-26 블레어 큐. 퍼거슨 중성 ｐ1 특이성 기를 갖는 인자 ｘａ의 억제제
IL136637A0 (en) * 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
ATE306481T1 (de) * 1999-05-12 2005-10-15 Ortho Mcneil Pharm Inc Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
JP2003509412A (ja) * 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
DZ3347A1 (fr) * 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
US6604974B2 (en) * 2000-12-22 2003-08-12 Thomson Licensing S.A. Method and apparatus for applying crosswires to a tension focus mask
CN100509790C (zh) * 2002-06-29 2009-07-08 赞塔里斯有限公司 芳基羰基哌嗪和杂芳基羰基哌嗪及其治疗良性和恶性肿瘤疾病的用途
GB0226178D0 (en) * 2002-11-11 2002-12-18 Johnson Matthey Plc Desulphurisation
BRPI0407088A (pt) * 2003-01-28 2006-01-24 Aventis Pharma Sa Produtos n-aril-heteroaromáticos, composições contendo os mesmos e seu uso

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004099154A3 *

Also Published As

Publication number Publication date
CA2525325A1 (en) 2004-11-18
MXPA05011775A (es) 2006-02-17
JP2006525355A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
US20040220170A1 (en) Pyrazole-amides and sulfonamides as sodium channel modulators
US7074805B2 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
RU2059622C1 (ru) Производные пиразола или их фармацевтически приемлемые кислотно-аддитивные соли
ES2315704T3 (es) Compuestos azabiciclicos fusionados que inhiben el receptor vainilloide de subtipo 1 (vr1).
CA2362381C (en) Amide compounds and medicinal use thereof
CN101511821B (zh) 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂
EP4192828A1 (de) Substituierte pyridinderivate als sarm1-inhibitoren
US20030158188A1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20060211739A1 (en) Use of selective P2X7 receptor antagonists
KR20070114762A (ko) 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
JP2004527486A (ja) 新規なピリミジン化合物
US7411073B2 (en) Selective non-steroidal glucocorticoid receptor modulators
US7037927B2 (en) Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20060189639A1 (en) Antagonists of the mGlu receptor and uses thereof
WO2007007778A1 (ja) プロスタグランジンｄ合成酵素を阻害するベンゾイミダゾール化合物
EP1620405A2 (de) Pyrazolamide und sulfonamide als natriumkanal modulatoren
JP4629037B2 (ja) 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−（アミノカルボニル）エト−１−イル）アミド誘導体および関連化合物
US20040121994A1 (en) Novel amides that activate soluble guanylate cyclase
WO2003076408A2 (en) Indazole derivatives that are activators of soluble guanylate cyclase
US20040048866A1 (en) Indazole derivatives that are activators of soluble guanylate cyclase
JP6313264B2 (ja) ケイ皮酸アミド誘導体を含有する医薬
TWI646072B (zh) 桂皮酸醯胺衍生物
JP2006525361A (ja) ブラジキニンｂ１受容体アンタゴニストとしての選択された置換ピラゾール誘導体および関連化合物
US20040192680A1 (en) Novel amides that activate soluble guanylate cyclase
US20030232836A1 (en) Acetamides and benzamides that are useful in treating sexual dysfunction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051031

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KORT, MICHAEL E.

Inventor name: ATKINSON, ROBERT N.

Inventor name: SHI, LEI

Inventor name: GREGG, ROBERT J.

Inventor name: GROSS, MICHAEL F.

Inventor name: DRIZEN, IRENE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091103